Would be nice if this included Dacogen
Abstract Number: 4624
Presentation Title: Identification of novel DNA methylation markers to track patient’s response to DNA demethylation agents
Presentation Time: Tuesday, Apr 09, 2013, 4:20 PM - 4:35 PM
Location: Room 147, Washington Convention Center
Author Block: Xiaojing Yang1, Han Han1, Marianne B. Treppendahl2, Yvonne C. Tsai1, Casey O’Connell3, Dan Weisenberger4, Fides Lay1, Kirsten Grønbæk2, Gangning Liang1, Peter A. Jones1. 1USC Norris Comprehensive Cancer Center, Los Angeles, CA; 2Department of Hematology, Rigshospitalet, Copenhagen, Denmark; 3Jane Anne Nohl Division of Hematology,University of Southern California, Los Angeles, CA; 4Epigenome Center, University of Southern California, Los Angeles, CA
Abstract Body: This abstract has been withheld from posting due to its inclusion in the AACR Annual Meeting 2013 Official Press Program. It will be posted following its presentation.
• AT13387 exhibits dose dependent systemic exposure and linear
pharmacokinetics. Half-life of AT13387 in GIST patients across Phase 1 and
Phase 2, range between 6.8 – 11.2 hours.
• HSP70 induction of 2-7 fold magnitude was observed representing
pharmacodynamic evidence of target engagement.
• AT13387 demonstrated clinical activity after failure of multiple TKI treatment
with 2 PR of 14 treated patients in Phase1 and Phase 2 thus far.
• Phase 1 DLTs consisted mainly of multiple Gr 2 Adverse Events of GI toxicities
(diarrhea, vomiting), systemic infusion reactions, and fatigue. Few patients had
Gr 3 toxicities and no Gr 4 AEs were reported. Visual disturbances were all Gr 1
with only 1 patient reported as Gr 3 due to ERG changes. All were transient
and reversible. Visual disturbances are considered on target pharmacological
class effects of potent HSP90 inhibition. GIST patients safety profile similar to
overall enrolled population.
• AT13387 is a promising agent in GIST, including TKI-resistant c-KIT positive and
c-Kit negative GIST.
• Phase 2 study in combination with imatinib is ongoing for imatinib-resistant
not all reverse splits end up being negative
look at CXW in May of 2001 (1 for 10)
split was announced 5/08/01 and was reverse split 5/18/01
Looks more like a hachet job to me, unless he forgot what he said in the first paragraph about the stock split.
"What is the general opinion here about Orathecin's chances of approval?"
Even a lot of people who are long this stock don't give it a lot of chance. I personally think it should be approved. Have you seen the survival curve for the PhaseIII vs best care? It looks like a 50-100 day advantage for least 25-30% of the curve. Median survival only increased 15 days and was not statically inportant p=.626 As aggressive as the disease is, I think median survival is a poor comparison.
to see the survival curve see slide 23 of the Rodmen & Renshaw conference
Just to let everyone know I am not always a complete dunce (being in almost last place in 2004)
here is a link to two of my 2001 picks
which I still own (only owned Supergen of my 2004 picks.)
"What I don't remember was the conversion ratio to common and whether that was even a factor."
I don't remember how much was converted. I think it was a substantial amount. As to the conversion factor, it varied somewhat, but if you had 100 shares of PZN, it got you 6 shares of the pref B and that could get you as many as 150 shares of common, so 100 common turned into 250 shares and then 25 shares. That's why between the 2 events I figure aboutt a 1:4 reverse split.
"1. what is the fair market value per share for quarterly distribution on 12% pfd. conv. ser B for payment date 3/31/03? I have every qtr. from 1/02/01 to 1/02/03 but not 3/31/03."
Or how about how about since 1/2001?
"He thinks this stock is a piece of sh-t and jokes everytime I bring it up."
Has your financial advisor outperformed what he thinks is a pos over the last 2 years?
"I know one thing for sure I never owed 17,000 shares of PZN and I don't know how I ended up with what I have."
Although CXW did have a 1:10 reverse split, you are probably are right when you say you never had 17000 shares. If you had 6800 shares of PZN and converted your preferred B distribution to common you would now have about 1700 shares. When you combine the two events together it would effectively be a 1:4 for reverse split. Now there were different conversion dates with slightly different ratios so you may have had more than 6800 shares.
"The shares can be redeemed at $24.46 after the company's notes are paid down. Which notes?" I beleive the notes are 12% and I thought about 90% of them were paid off. The link below shows a zero balance at 12/31/03 however. During the conference call they said they expected to retire both the preferred A & B this year.
It seems with a p value that low there had to be a larger benefit for those whose event occurred later than median. This pct wise does not seem quite as good as the orathecin trial, I think it had p value of only .5 (the survival endpoint) This is even a smaller trial. Any chance I am right?